The Role of Hypoxia in Shaping the Recruitment of Proangiogenic and Immunosuppressive Cells in the Tumor Microenvironment

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2018 Apr 10

PMID 29628788

Citations 24

Authors

Salem Chouaib

Viktor Umansky

Claudine Kieda

Affiliations

Soon will be listed here.

Abstract

Hypoxia characterizes growing tumors and contributes significantly to their aggressiveness. Hypoxia-inducible factors (HIFs 1 and 2) are stabilized and act differentially as transcription factors on tumor growth and are responsible for important cancer hallmarks such as pathologic angiogenesis, cellular proliferation, apoptosis, differentiation and genetic instability as well as affecting tumor metabolism, tumor immune responses, invasion and metastasis. Taking into account the tumor tissue as a whole and considering the interplay of the various partners which react with hypoxia in the tumor site lead to reconsideration of the treatment strategies. Key limitations of treatment success result from the adaptation to the hypoxic milieu sustained by tumor anarchic angiogenesis. This raises immune tolerance by influencing the recruitment of immunosuppressive cells as bone marrow derived suppressor cells (MDSC) or by impairing the infiltration and killing of tumor cells by cytotoxic cells at the level of the endothelial cell wall of the hypoxic tumor vessels, as summarized in the schematic abstract.

Citing Articles

The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies.

Wang Q, Yu M, Zhang S Front Immunol. 2025; 15:1440830.

PMID: 39877377 PMC: 11772360. DOI: 10.3389/fimmu.2024.1440830.

Effect of Hypoxia on Siglec-7 and Siglec-9 Receptors and Sialoglycan Ligands and Impact of Their Targeting on NK Cell Cytotoxicity.

Nawafleh H, Zeinelabdin N, Greene M, Krishnan A, Ho L, Genead M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598355 PMC: 11597189. DOI: 10.3390/ph17111443.

ALKBH5 regulates arginase 1 expression in MDSCs and their immunosuppressive activity in tumor-bearing host.

Feng L, Li M, Ma J, Wang W, Wang S, Mao Z Noncoding RNA Res. 2024; 9(3):913-920.

PMID: 38638146 PMC: 11024866. DOI: 10.1016/j.ncrna.2024.03.003.

Value of the NF-κB signalling pathway and the DNA repair gene PARP1 in predicting distant metastasis after breast cancer surgery.

Pan K, Li X, He J, Lei Y, Yang Y, Jiang D Sci Rep. 2024; 14(1):4402.

PMID: 38388665 PMC: 10883999. DOI: 10.1038/s41598-023-49156-4.

Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer.

Lian M, Mortoglou M, Uysal-Onganer P Curr Issues Mol Biol. 2023; 45(12):9778-9792.

PMID: 38132457 PMC: 10742176. DOI: 10.3390/cimb45120611.

References

Kanterman J, Sade-Feldman M, Baniyash M . New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 2012; 22(4):307-18. DOI: 10.1016/j.semcancer.2012.02.008. View

Koh Y, Kim H, Hwang S, Lee J, Oh N, Jung K . Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell. 2010; 18(2):171-84. DOI: 10.1016/j.ccr.2010.07.001. View

Bielawska-Pohl A, Crola C, Caignard A, Gaudin C, Dus D, Kieda C . Human NK cells lyse organ-specific endothelial cells: analysis of adhesion and cytotoxic mechanisms. J Immunol. 2005; 174(9):5573-82. DOI: 10.4049/jimmunol.174.9.5573. View

Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y . A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther. 2017; 10:2115-2126. PMC: 5396961. DOI: 10.2147/OTT.S130481. View

Whiteside T, Mandapathil M, Schuler P . The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem. 2011; 18(34):5217-23. PMC: 3721332. DOI: 10.2174/092986711798184334. View

Noman M, Chouaib S . Targeting hypoxia at the forefront of anticancer immune responses. Oncoimmunology. 2015; 3(12):e954463. PMC: 4353170. DOI: 10.4161/21624011.2014.954463. View

De Bock K, Georgiadou M, Carmeliet P . Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 2013; 18(5):634-47. DOI: 10.1016/j.cmet.2013.08.001. View

Sitkovsky M, Hatfield S, Abbott R, Belikoff B, Lukashev D, Ohta A . Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res. 2014; 2(7):598-605. PMC: 4331061. DOI: 10.1158/2326-6066.CIR-14-0075. View

Kuo H, Lin C, Lam H, Lin P, Chan H, Tseng J . PTEN overexpression attenuates angiogenic processes of endothelial cells by blockade of endothelin-1/endothelin B receptor signaling. Atherosclerosis. 2012; 221(2):341-9. DOI: 10.1016/j.atherosclerosis.2010.08.067. View

10.

Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

11.

Giuliani M, Janji B, Berchem G . Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget. 2017; 8(14):24031-24044. PMC: 5410361. DOI: 10.18632/oncotarget.15234. View

12.

Gajewski T, Woo S, Zha Y, Spaapen R, Zheng Y, Corrales L . Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013; 25(2):268-76. DOI: 10.1016/j.coi.2013.02.009. View

13.

Janji B, Viry E, Moussay E, Paggetti J, Arakelian T, Mgrditchian T . The multifaceted role of autophagy in tumor evasion from immune surveillance. Oncotarget. 2016; 7(14):17591-607. PMC: 4951235. DOI: 10.18632/oncotarget.7540. View

14.

Collet G, Szade K, Nowak W, Klimkiewicz K, El Hafny-Rahbi B, Szczepanek K . Endothelial precursor cell-based therapy to target the pathologic angiogenesis and compensate tumor hypoxia. Cancer Lett. 2015; 370(2):345-57. DOI: 10.1016/j.canlet.2015.11.008. View

15.

De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong B, Cantelmo A . Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013; 154(3):651-63. DOI: 10.1016/j.cell.2013.06.037. View

16.

Garrido F, Algarra I, Garcia-Lora A . The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother. 2010; 59(10):1601-6. PMC: 11029827. DOI: 10.1007/s00262-010-0893-2. View

17.

Parker K, Beury D, Ostrand-Rosenberg S . Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res. 2015; 128:95-139. PMC: 4662416. DOI: 10.1016/bs.acr.2015.04.002. View

18.

Junger W . Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011; 11(3):201-12. PMC: 4209705. DOI: 10.1038/nri2938. View

19.

Allard B, Beavis P, Darcy P, Stagg J . Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol. 2016; 29:7-16. DOI: 10.1016/j.coph.2016.04.001. View

20.

Chiu D, Xu I, Lai R, Tse A, Wei L, Koh H . Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology. 2016; 64(3):797-813. DOI: 10.1002/hep.28655. View